After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

A recently launched video series from the Biotechnology Innovation Organization (BIO) seeks to show how biotech may be able ...

Viatris in Egypt, a part of global healthcare company Viatris, announced the launch of Norvasc Val, a combination therapy for ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

Viatris said its global restructuring initiative was designed to ensure the new company was “set up to achieve its mission, deliver sustainable value to patients, customers, ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the company to reconsider the drug’s future. The Phase III study (NCT06400511) ...

Viatris is a relatively new company that started trading on Nov. 17, 2020. The entity was formed when pharma giant Pfizer spun off its off-patent medicine unit Upjohn, which merged with the ...

Viatris looks to boast a safe dividend and decent balance sheet. So, should investors buy the stock? Well, the stock is trading at a forward price-to-earnings (P/E) ratio of 4.